In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT), with a price target of $15. The company’s shares opened today at $3.53, close to its 52-week low of $3.22.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 20.0% and a 43.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Collegium Pharmaceutical, and Paratek Pharmaceuticals.
Currently, the analyst consensus on Conatus Pharmaceuticals is Strong Buy and the average price target is $17.25, representing a 388.7% upside.
In a report released today, Oppenheimer also reiterated a Buy rating on the stock with a $14 price target.
See today’s analyst top recommended stocks >>
Based on Conatus Pharmaceuticals’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $8.8 million and GAAP net loss of $4.36 million. In comparison, last year the company earned revenue of $7 million and had a GAAP net loss of $3.62 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Conatus Pharmaceuticals, Inc. is a biotechnology company that engages in the development and commercialization of medicines to liver diseases treatment. It focuses in development of Emricasan, orally active protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death or apoptosis for the interruption of progress of liver disease. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in Dan Diego, CA.
Read More on CNAT:
Conatus Pharmaceuticals (CNAT): Analyst Is Putting Pen to Paper to Determine the Impact of Emricasan’s Setback
Conatus Pharmaceuticals (CNAT): Oppenheimer Advises Investors to Wait for the Next Catalyst
What Spooked Conatus Pharmaceuticals (CNAT) Investors This Evening
Conatus Pharmaceuticals Inc (CNAT): Analyst Looks Forward to “Large Catalysts” Lying Ahead
